Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indications. The initial positive results of PP2A activators in vitro and mouse models of AML are prom...

Primary sensory afferent outgrowth within the developing longitudinal pathway of the spinal cord is important for intrasegmental and intersegmental communication that underlies coordination and development of reflexes and contributes to sensory perception. The endogenous mechanisms that regulate primary sensory afferent extension are the primary focus of this dissertation. This dissertation tes...

Background: Fingolimod is approved by EMA as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). Experience with fingolimod in real life is still limited. Aim of our study was to report data on fingolimod effectiveness in a real life cohort of Italian active RRMS patients, naïve to second-line agents, followed for 2 years. Fingolimod was a part of the patients’ regular tr...

BACKGROUND Multiple sclerosis (MS) is a complex disease with many therapeutic options. Little is known about how neurologists select particular disease-modifying therapies (DMTs) for their patients. OBJECTIVE To understand how neurologists make decisions regarding the prescription of DMTs for patients with MS, and to explore neurologists' experiences with individual DMTs. METHODS From Decem...

This review summarizes Phase III clinical trial data available for fingolimod. The main purpose is to evaluate the benefit-risk profile of fingolimod, the first oral compound available for treatment of multiple sclerosis (MS) and just recently approved by the European authorities. The authors place this evaluation in the context of the known safety and efficacy profile of established compounds ...

Fingolimod 0.5 mg q.d. (once daily) has been approved for the treatment of patients with relapsing and remitting forms of multiple sclerosis (RRMS). Fingolimod at two doses (0.5 and 1.25 mg) showed superior effectiveness in the frequency of relapse with little difference between the two dose groups. At the same time, fingolimod manifests a number of dose-dependent adverse events. Given the safe...

■■ Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians for Management of Multiple Sclerosis Agents Miller et al. (“Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians”) published in the January/February 2012 issue of JMCP present the results of a modif...

Case report. A 55-year-old Caucasian HIV-negative man diagnosed with relapsing-remitting MS in 2013 and an Expanded Disability Status Scale (EDSS) score of 2.0 had received 20 infusions of natalizumab over 21 months without a history of prior immunotherapy. John Cunningham–virus (JCV) antibodies were positive at the initiation of treatment (index: 0.4). Natalizumab was then discontinued because...